Article Details
Retrieved on: 2024-08-21 16:48:18
Tags for this article:
Click the tags to see associated articles and topics
Summary
BridgeBio Pharma's establishment of GondolaBio, funded by top life sciences investors, demonstrates the biopharma sector's strategy of focusing on niche, rare disease treatments, paralleling earlier spinouts like the KRAS-targeted BridgeBio Oncology Therapeutics.
Article found on: finance.yahoo.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here